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Abstract
Introduction Reliable predictive and prognostic markers for
routine diagnostic purposes are needed for breast cancer
patients treated with neoadjuvant chemotherapy. We evaluated
protein biomarkers in a cohort of 116 participants of the
GeparDuo study on anthracycline/taxane-based neoadjuvant
chemotherapy for operable breast cancer to test for
associations with pathological complete response (pCR) and
disease-free survival (DFS). Particularly, we evaluated if
interactions between hormone receptor (HR) and human
epidermal growth factor receptor 2 (HER2) expression might
lead to a different clinical behavior of HR+/HER2+ co-
expressing and HR+/HER2- tumors and whether subgroups of
triple negative tumors might be identified by the help of Ki67
labeling index, cytokeratin 5/6 (CK5/6), as well as
cyclooxygenase-2 (COX-2), and Y-box binding protein 1 (YB-1)
expression.
Methods Expression analysis was performed using
immunohistochemistry and silver-enhanced in situ hybridization
on tissue microarrays (TMAs) of pretherapeutic core biopsies.
Results pCR rates were significantly different between the
biology-based tumor types (P = 0.044) with HR+/HER2+ and
HR-/HER2- tumors having higher pCR rates than HR+/HER2-
tumors. Ki67 labeling index, confirmed as significant predictor of
pCR in the whole cohort (P = 0.001), identified HR-/HER- (triple
negative) carcinomas with a higher chance for a pCR (P =
0.006). Biology-based tumor type (P = 0.046 for HR+/HER2+
vs. HR+/HER2-), Ki67 labeling index (P = 0.028), and treatment
arm (P = 0.036) were independent predictors of pCR in a
multivariate model. DFS was different in the biology-based
tumor types (P < 0.0001) with HR+/HER2- and HR+/HER2+
tumors having the best prognosis and HR-/HER2+ tumors
showing the worst outcome. Biology-based tumor type was an
independent prognostic factor for DFS in multivariate analysis (P
< 0.001).
Conclusions Our data demonstrate that a biology-based breast
cancer classification using estrogen receptor (ER),
progesterone receptor (PgR), and HER2 bears independent
predictive and prognostic potential. The HR+/HER2+ co-
expressing carcinomas emerged as a group of tumors with aPage 1 of 11
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favorable prognosis. HR+/HER2- tumors had a good prognosis
irrespective of a pCR, whereas patients with HR-/HER- and HR-
/HER+ tumors, especially if they had not achieved a pCR, had
an unfavorable prognosis and are in need of additional treatment
options.
Trial registration ClinicalTrials.gov identifier: NCT00793377
Introduction
Neoadjuvant chemotherapy or preoperative systemic therapy
is increasingly considered for patients with operable breast
cancer [1,2] as survival rates are similar as in patients receiv-
ing standard post-operative chemotherapy and the rate of
breast conserving surgery can be significantly increased in
patients treated with neoadjuvant chemotherapy [3,4]. One of
the main aims of neoadjuvant chemotherapy is to achieve a
pathological complete response (pCR; i.e. absence of malig-
nant cells at the tumor site) because pCR has been found to
be associated with longer disease-free and overall survival
rates [2,5-7]. However, it is not clear if this predictive value is
valid for all patients, as a small proportion of patients with pCR
still experience distant relapse [8]. In general, pCR rates with
classical chemotherapy are rather low and range from 10% to
26% depending on the applied regimes [9]. To date, only a
few tumor markers exist for the prediction of pCR, e.g. low
tumor differentiation and negative hormone receptor (HR) sta-
tus [10,11]. Therefore, reliable predictive and prognostic
markers are needed for the optimal selection of patients who
might benefit from a neoadjuvant chemotherapy, i.e. who have
the chance to achieve a pCR and remain disease-free on the
long term.
Studies investigating gene expression profiles in breast can-
cer have defined different breast cancer subclasses that were
based on tumor biology-based characteristics [12-15]. Lumi-
nal cancers were characterized by the expression of HR, the
HER2 cluster showed an over-expression of HER2 and asso-
ciated genes, and basal-like cancers were negative for HR and
HER2 ("triple negative") and express basal cytokeratins as
well as the proliferative cluster of genes [12]. Despite the fact
that these biology-based tumor types are usually seen as dif-
ferent entities, in clinical practice there is a remarkable overlap
between HR and HER2 positive cases. As data from preclini-
cal models suggest an interaction between the HER2 and HR
pathways [16,17], we evaluated the hypothesis that these
interactions might lead to a different clinical behavior of HR+/
HER2+ co-expressing and HR+/HER2- tumors. This might be
reflected in a different response to anthracycline/taxane-based
neoadjuvant chemotherapy as well as in a different DFS. In
addition, it has been suggested that the subgroup of HR-/
HER2- (triple negative) carcinomas might constitute a mixture
of different biologically and prognostically heterogeneous
tumors [18,19]. Therefore, we evaluated the hypothesis that a
subclassification of these carcinomas might be possible using
Ki-67 proliferation index, cytokeratin 5/6 (CK5/6), cyclooxyge-
nase-2 (COX-2), as well as Y-box binding protein 1 (YB-1)
expression, for the latter two a role in breast cancer progres-
sion has been demonstrated previously [20,21]. We investi-
gated our hypotheses in a cohort of pretherapeutic core
biopsies from the neoadjuvant GeparDuo study, in which
patients with operable breast cancer have been treated with
either dose-dense doxorubicin plus docetaxel (ddADOC) or
conventionally-dosed doxorubicin plus cyclophosphamide fol-
lowed by docetaxel (AC-DOC) [22].
Materials and methods
Study population and histopathological examination
The multicenter randomized prospective neoadjuvant phase III
GeparDuo trial (NCT00793377) investigated 913 patients
with operable breast cancer (T2-3, N0-2, M0) between June
1999 and September 2001 comparing doxorubicin 50 mg/m2
plus docetaxel 75 mg/m2 every 14 days for four cycles with fil-
grastim support (ddADOC, n = 451) or four cycles doxoru-
bicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 every 21
days followed by docetaxel 100 mg/m2 every 21 days for four
cycles (AC-DOC, n = 453). The trial was conducted in com-
pliance with the Helsinki Declaration. The protocol was
reviewed and approved by all responsible local ethics commit-
tees. The leading ethics committee was located at the Johann-
Wolfgang Goethe University, Frankfurt, Germany (Approval
Number: 80/99). Consent of patient, pathologist and investi-
gator to supply tumor material of biopsy and surgery for central
pathologic evaluation and examination of predictive factors
was available. All patients received tamoxifen simultaneously,
irrespective of HR status [22]. The primary endpoint was the
incidence of pCR in the breast and axillary nodes (absence of
invasive and non-invasive (carcinoma in situ) tumor cells in the
surgical specimen including lymph nodes). A statistical analy-
sis using a pCR definition that also includes cases with resid-
ual in-situ carcinoma yielded similar results (not shown). For
219 patients tissue from the presurgical biopsy containing
more than 30% tumor tissue was available in our tissue bank.
These samples were used to construct a tissue microarray. In
the statistical evaluation, only cases that could be evaluated at
least for ER and HER2 were included (116 cases). Stained
slides were digitized by a slide scanner (Mirax Scan, Zeiss,
Jena, Germany), and were subsequently evaluated using a
custom-made software for whole slide imaging. For clinico-
pathological characteristics of our study cohort see additional
data file 1. Data according to clinical tumor stage (cT) and clin-
ical lymph node state (cN), patient age, pCR and outcome
data were derived from the clinical study database. Punch
biopsies were re-evaluated according to tumor histology and
grading (Bloom-Richardson modified by Elston and Ellis) [23]Page 2 of 11
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available from 105 patients for a median follow-up time without
event of 57.6 months.
Immunohistochemical staining and silver-enhanced in 
situ hybridization (SISH)
Immunohistochemical staining of tissue microarray slides was
performed using the Discovery XT autostainer (Ventana, Tus-
con, AZ, USA) according to the manufacturer's instructions.
The following antibodies were used: rabbit monoclonal anti-
body against human ERα (clone SP1, Neomarkers (Lab
Vision), Fremont, CA, USA, 1:50); mouse monoclonal anti-
body against human progesterone receptor PgR (clone PgR
636, Dako, Glostrup, Denmark, 1:50); rabbit polyclonal anti-
body against human HER2 (HercepTest™ antibody, Dako,
1:500); mouse monoclonal antibody against human Ki67
(clone MIB-1, Dako, 1:50); mouse monoclonal antibody
against human CK5/6 (clone D4/16B4, Zymed (Invitrogen),
Carlsbad, CA, USA, 1:25). Immunohistochemical staining for
YB-1 (Biogenes, Berlin, Germany, 1:1000) and COX-2 (Cay-
man Chemical Company, Ann Arbor, MI, USA, 1: 5000) was
performed manually as described previously [20,21]. SISH
analysis was performed on a Benchmark XT autostainer (Ven-
tana) using the INFORM HER2 probe (Ventana) according to
the manufacturer's instructions.
ER and PgR immunohistochemistry was scored positive if at
least 10% of tumor cell nuclei showed a staining signal. Data
on PgR expression were available for 105 cases. HER2 reac-
tivity was assessed according to the ASCO/CAP guidelines
[24]: Cases with a uniform intense membranous staining of >
30% of tumor cells (3+) or those with a weak membranous
staining (2+) and HER2 amplification in SISH were desig-
nated as HER2 positive. For the assessment of the prolifera-
tion rate the percentage of tumor cell nuclei positive for Ki67
was estimated (106 cases). According to Petit et al. a cutoff
of 20% of stained tumor cell nuclei was used for dichotomiza-
tion [25]. Any expression of CK5/6 in expression tumor cells
was scored as positive (114 cases). For the interpretation of
COX-2 and YB-1 staining the immunoreactivity score was
used comprising both staining intensity and rate of stained
tumor cells, as described previously (101 and 106 cases,
respectively) [20]. Immunohistochemistry was evaluated by at
least two pathologists who were blinded towards the patients'
outcome (SDE and BM).
Statistical evaluation
Correlation analyses were performed by the use of binary
logistic regression analysis, and as indicated by χ2 test. Sur-
vival times were compared by Cox regression analysis and the
Kaplan-Meier method. P-values ≤ 0.05 were considered signif-
icant. For statistical procedures, the software packages
SPSSv16.0 (Chicago, IL, USA) and GraphPad Prism 5.01 (La
Jolla, CA, USA) were used.
Results
Distribution of clinico-pathological parameters in the 
study group
The study cohort was derived from the GeparDuo study that
comprised patients with operable breast cancer (cT1-3, cN0-
2). Most patients had ductal-invasive breast cancer, a minor
subgroup had lobular carcinomas and few patients had can-
cers of rare histology, which are summarized as "others" in our
study (cribriform, metaplastic). Thirteen patients in the study
achieved a pCR (11.2%). The rate of patients receiving ddA-
DOC and AC-DOC therapy was similar (P > 0.05). The distri-
bution of clinico-pathological parameters was comparable to
the full study population [see additional data file 1].
Immunohistochemical findings in the study cohort
ER was expressed by 63 (54.3%) invasive breast carcinomas
(Figure 1A). Fewer tumors were positive for PgR (44 cases,
37.9%, Figure 1B). A co-expression of ER and PgR was found
in 37 cases (31.9%). A HER2 over-expression was detected
in 27 cases (23.3%, Figure 1C, D). Ki67 (MIB-1) expression
ranged from 0 to 90%, median 5%; 85 tumors showed
<=20% of positive nuclei (80.2%), 21 tumors had a prolifera-
tion rate of > 20% (19.8%; Figure 1E). Seven carcinomas
(6.1%) showed evidence of a CK5/6 expression, which was
mostly focally (Figure 1F). COX-2 was expressed by 74
tumors (73.3%, Figure 1G), and expression of YB-1 was
detected in the cytoplasm of tumor cells in 35 cases (33.0%,
Figure 1H).
Biology-based tumor types according to HR and HER2 
status
Data on ER, PgR, and HER2 expression were used to classify
breast carcinomas. With a focus on different combinations of
these markers, we distinguished four distinct, non-overlapping
classes: tumors positive for ER and/or PgR expression and
negative for HER2 expression were designated as HR+/
HER2- (57 cases, 49.1%). HER2 expressing tumors without
HR expression were designated as HR-/HER2+ (13 cases,
11.2%). In case of a co-expression of HR and HER2 the tumor
was included in the HR+/HER2+ category (13 cases, 11.2%),
while tumors negative for ER, PgR and HER2 were designated
as HR-/HER2- (triple negative, 33 cases, 28.4%).
Association of biology-based tumor types with clinico-
pathological parameters as well as YB-1 and COX-2 
expression
Biology-based tumor types were significantly associated with
tumor grading: While HR+/HER2- positive tumors were most
frequently well or moderately differentiated, the proportion of
G3 tumors was higher in the HR-/HER2+ as well as HR-/HER-
group (P = 0.004, χ2 test). Consistent with HER2 being the
target of the transcription factor YB-1, HER2 positive tumors
(HR-/HER2+ or HR+/HER2+) were most often YB-1 positive
(66.7% and 58.3%), as previously reported [26,27], while a
YB-1 expression was rare in the HR+/HER2- and HR-/HER-Page 3 of 11
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icant correlations could be established between COX-2
expression and any of the subgroups investigated. In line with
previous reports, CK5/6 expression was mainly found in HR-/
HER2- tumors (6/31 cases, 19.4%, P = 0.005, χ2 test)
[28,29].
Association of biology-based tumor types with pCR
The pCR rate was significantly different between biology-
based tumor types (P = 0.044, Figure 2, Table 1). Patients
with HR+/HER2- tumors had the lowest pCR rate: only 1 of
57 (1.8%) of those patients experienced a pCR. In contrast, 8
of 33 (24.2%) patients with HR-/HER2- tumors achieved a
pCR. The odds ratio for achieving a pCR in the HR-/HER2-
group was 17.92 as compared to the HR+/HER2- subgroup
(P = 0.008). Interestingly, patients with HR+/HER2+ tumors
had a similar pCR rate than those with HR-/HER2- tumors
(23.1%, hazard ratio HR+/HER2+ vs. HR+/HER2- 16.8, P =
0.019, Table 1). In the HR-/HER2+ subgroup, however, the
pCR rate was not significantly different from the HR+/HER2-
subgroup (7.7%; OR 4.67 P = 0.288).
Association of other factors with pCR
The pCR rate was significantly correlated with Ki67 labeling
index (P = 0.001), CK5/6 expression (P = 0.017), tumor
grade (P = 0.003), and treatment arm (P = 0.034) (Table 1
and Figure 2).
Association with pCR - multivariate analysis
In an exploratory multivariate logistic regression analysis
including the significant predictive markers from univariate
analysis (biology-based tumor types, Ki67 labeling index,
CK5/6 expression, grading, treatment arm; Table 2), the HR+/
HER2+ subgroup was independently linked to a higher pCR
rate (P = 0.046; compared to HR+/HER2-) while the HR-/
HER2- group lost its predictive significance. Furthermore,
Ki67 staining and treatment arm were of independent predic-
tive value (P = 0.028 and P = 0.036, Table 2).
Association of HR-/HER2-(triple negative) subgroups 
with pCR
We evaluated the hypothesis that molecular markers could be
used to divide the triple-negative tumors into different sub-
groups wit different clinical outcome. As shown in Table 3,
HR-/HER2- tumors could be divided into subgroups with dif-
ferent pCR rates according to their proliferation rate. HR-/
Figure 1
(A) Strong expression of ER in a ductal-invasive breast carcinomaa . (b) 
Strong expression of PgR in a moderately differentiated breast carci-
noma. (c) Complete membranous expression of HER2 in a high-grade 
breast carcinoma (3+). (d) Silver-enhanced in situ hybridization (SISH): 
multiple Her2 gene copies (black dots) in tumor cell nuclei of a Her2-
amplified breast carcinoma. (e) Nuclear expression of Ki67 in a poorly 
differentiated breast carcinoma. (f) Focal perimembranous expression 
of CK5/6 in a high grade tumor. (g) Moderate cytoplasmic expression 
of COX-2 in a ductal-invasive breast carcinoma. (h) Diffuse cytoplas-
mic expression of YB-1 in invasive breast cancer nests.
Figure 2
Rate of patients achieving a pCR in dependence of biology-based tumor ty e (p: likeli ood ratio test), Ki67 lab ling index, CK5/6 expres-sion, grading, and pr -operativ  chemotherapy
tumor type (p: likelihood ratio test), Ki67 labeling index, CK5/6 expres-
sion, grading, and pre-operative chemotherapy. p: logistic regression.Page 4 of 11
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Table 1
Correlation with pCR (univariate logistic regression analysis)
n events % pCR OR 95% CI p
age (per year) 116 13 - 0.96 0.90-1.01 0.128
biology-based tumor type 116 13 0.044a
HR+/HER2- 57 1 1.8 1.00
HR+/HER2+ 13 3 23.1 16.80 1.59-178.12 0.019
HR-/HER2+ 13 1 7.7 4.67 0.27-79.96 0.288
HR-/HER2- 33 8 24.2 17.92 2.13-151.04 0.008
Ki67 106 12
<= 20% 85 5 5.9 1.00
> 20% 21 7 33.3 8.00 2.22-28.79 0.001
CK5/6 114 13
negative 107 10 9.3 1.00
positive 7 3 42.9 7.28 1.42-37.22 0.017
COX-2 101 12
negative 27 5 18.5 1.00
positive 74 7 9.5 0.46 0.13-1.60 0.221
YB-1 106 12
negative 71 8 11.3 1.00
positive 35 4 11.4 1.02 0.28-3.36 0.980
therapy arm 116 13
ddADOC 61 3 4.9 1.00
AC-DOC 55 10 18.2 4.30 1.12-16.53 0.034
histology 116 13 0.767a
ductal-invasive 98 12 12.2 1.00
lobular 14 0 0.0 0.00 0.00- - 0.999
others 4 1 25.0 2.39 0.23-24.86 0.466
grade 116 13
G1-2 76 3 3.9 1.00
G3 40 10 25.0 8.11 2.09-31.55 0.003
cT 116 27 0.570a
cT1 9 2 22.2 1.00
cT2 87 9 10.3 0.40 0.07-2.25 0.300
cT3 20 2 10.0 0.39 0.05-3.32 0.388
cN 116 27
cN0 79 8 10.1 1.00
cN1-2 37 5 13.5 1.39 0.42-4.57 0.591
OR: odds ratio; CI: confidence interval; a: overall significance.
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increased Ki67 level: a significantly higher pCR rate was seen
in tumors with > 20% positive nuclei (63.6% vs. 0%, P <
0.0001, χ2 test), and an increase of 10% of Ki67-labeled
tumor cells equaled a hazard ratio of 1.92 (P = 0.006, Table
3). Although the pCR rate in HR-/HER2- carcinomas was
higher when they expressed CK5/6 (37.5%) compared to
15% for CK5/6 negative tumors, the sub-classification by
CK5/6 was not a significant predictor. COX-2, or YB-1
expression were not relevant for response prediction in the
HR-/HER2- group.
Association of biology-based tumor types with DFS
Patient prognosis was significantly dependent on the biology-
based tumor type P < 0.0001, Figure 3A, Table 4): Interest-
ingly, the behavior of HER2 expressing tumors was dependent
on co-expression of HR. Thus, tumors from the HR+/HER2+
category had a relatively favorable prognosis similar to HR+/
HER2- cancers (hazard ratio 1.26 compared to HR+/HER2-,
P = 0.770; 3-year survival rate 90.0%). In contrast, a HR-/
HER2- status was associated with a significant deterioration
of the prognosis (hazard ratio 2.23 compared to HR+/HER2-
; 3-year survival 65.0%, P = 0.016) and patients with HR-/
HER2+ tumors had the shortest survival time of all groups
(hazard ratio 9.32 compared to HR+/HER2-; 3-year survival
33.3%, P < 0.0001). Patients with HR+/HER2- tumors had
the longest time to disease progression with a 3-year survival
rate of 96.3%.
Analyzing only the 95 patients without pCR we found the same
results, especially women with HR+/HER2- and HR+/HER2+
tumors relapsed in only 10 from 55 cases (P < 0.0001, log
rank test, 18.2%, Figure 3B). In contrast, women with HR-/
HER2+ cancers relapsed frequently, in 8 out of 11 cases
Table 2
Multivariate analysis (logistic regression and Cox regression analysis)
correlation with pCR correlation with survival
OR 95% CI p hazard ratio 95% CI p
biology-based tumor type 0.258a < 0.0001a
HR+/HER2- 1.00 1.00
HR+/HER2+ 14.28 1.05-194.31 0.046 1.88 0.39-9.04 0.432
HR-/HER2+ 5.35 0.25-116.83 0.287 16.78 5.75-48.97 < 0.0001
HR-/HER2- 6.01 0.53-67.84 0.147 4.24 1.62-11.12 0.003
Ki67
<= 20% 1.00
> 20% 10.37 1.29-83.28 0.028 - - -
CK5/6
negative 1.00
positive 0.51 0.04-7.57 0.627 - - -
therapy arm
ADoc 1.00
ACDoc 11.97 1.17-122.16 0.036 - - -
grade
G1-2 1.00
G3 5.59 0.93-33.70 0.061 - - -
ypN
cN0 1.00
cN1-2 - - - 2.77 1.24-6.18 0.013
pCR
no pCR 1.00
pCR - - - 0.18 0.02-1.43 0.104
OR: odds ratio; CI: confidence interval; a: overall significance.Page 6 of 11
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42.1%).
Association of other factors with DFS
Pathological lymph node state after chemotherapy (ypN) was
a further significant prognostic factor for DFS (P = 0.021,
Table 4). No other clinico-pathological factor or biomarker,
including Ki67 labeling index, had prognostic impact in the
whole study group or in the HR-/HER2- subgroup (data not
shown).
Association with DFS - multivariate analysis
An exploratory multivariate Cox regression analysis including
biology-based tumor types, nodal status and pCR (Table 2)
confirmed biology-based tumor type as an independent prog-
nostic factor for DFS. Thus, the HR-/HER2+ as well as the
HR-/HER2- subgroup remained significant risk factors for a
Table 3
Correlation of HR-/HER2- subgroups with pCR (univariate logistic regression analysis)
n events % pCR OR 95% CI p
HR-/HER2- subgroups
Ki67 (per 10%)
29 7 - 1.92 1.21-3.04 0.006
CK5/6 30 8
negative 24 5 20.8 1.00
positive 6 3 50.0 3.80 0.58-24.88 0.127
COX-2 26 7
negative 9 3 33.3 1.00
positive 17 4 23.5 0.62 0.10-3.66 0.593
YB-1 30 7
negative 22 5 22.7 1.00
positive 8 2 25.0 1.13 0.17-7.47 0.896
OR: odds ratio; CI: confidence interval.
Table 4
Correlation with disease-free survival (Cox regression analysis)
n events 3-year survival rate (%) hazard ratio 95% CI p
biology-based tumor type 105 27 < 0.0001a
HR+/HER2- 56 8 96.3 1.00
HR+/HER2+ 13 2 90.0 1.26 0.27-5.98 0.770
HR-/HER2+ 12 8 33.3 9.32 3.45-25.13 < 0.0001
HR-/HER2- 24 9 65.0 2.23 1.24-8.40 0.016
Ki67 96 21
<= 20% 79 16 87.7 1.00
> 20% 17 5 70.6 1.43 0.52-3.94 0.486
pCR 105 27
no pCR 95 26 80.0 1.00
pCR 10 1 90.0 0.29 0.04-2.15 0.227
ypN 105 27
ypN0 65 13 83.1 1.00
ypN1-2 40 14 52.4 2.46 1.142-5.302 0.021
CI: confidence interval.
a: overall significance.Page 7 of 11
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0.0001 and 0.003, respectively). Nodal state remained a sig-
nificant prognostic factor in multivariate analysis, too (P =
0.013).
Discussion
Our study demonstrates that breast cancer subclassification
based on HR and HER2 expression as used in standard diag-
nostics bears potential for the prediction of a pCR in patients
with operable breast cancer receiving neoadjuvant chemo-
therapy with anthracycline and taxane and has a prognostic
impact. Interestingly, the coexpression of HER2 and HR was
found to be relevant for prediction of therapy response as well
as assessment of long term benefit. HR+/HER2+ co-express-
ing tumors had a high response rate and showed a favorable
DFS similarly to HR+/HER2- tumors, which however,
responded rarely. A particularly low response rate as well as a
poor prognosis was seen for HR-/HER2+ breast cancers. Fur-
ther on, HR-/HER2- tumors were linked to a higher pCR rate,
yet relapsed significantly earlier if they did not achieve a pCR.
Even though the determination of HR and HER2 status is rou-
tinely performed in breast cancer diagnostics, the predictive
and prognostic value of a classification based explicitly on HR/
HER2 expression has been rarely analyzed and in part only
been reported in supplemental data. Basically, these studies
showed similar results to ours: Guarneri et al. found retrospec-
tively in a cohort of 1,731 breast cancer patients treated with
varying neoadjuvant anthracycline-based regimes that ER+/
HER2+ carcinomas had a higher pCR rate than ER+/HER2-
tumors (15.3% vs. 6%) [30]. The highest pCR rates in this
study were observed in ER-/HER2+ (29%) and in ER-/HER2-
carcinomas (22.4%). Five-year disease-free survival rate was
only slightly lower in ER+/HER2+ than in ER+/HER2- tumors
(66.3% vs. 60.2%) and was lowest in ER-/HER2+ tumors
(43.7%) just like in our study. Similarly, in a retrospective study
including 1,118 patients treated with various neoadjuvant
chemotherapeutic regimes Liedke et al. found equally high
pCR rates in ER+/HER2+ and ER-/HER2- carcinomas (21%
vs. 22%; ER+/HER2-: 5%, ER-/HER2+: 31%). Three-year
disease-free survival rate was similar in ER+/HER2+ and in
ER+/HER2- carcinomas (70% vs. 73%) and was as low in ER-
/HER2+ tumors as in ER-/HER2- tumors (61% and 63%)
[31]. In a study setting similar to ours, Carey et al. showed in
107 patients treated with anthracycline-based neoadjuvant
chemotherapy that in HR+/HER2+ tumors pCR rate was
higher than in HR+/HER2- tumors, and DFS was worse in
HR+/HER2+ co-expressing than in HR+/HER2- tumors, yet
was still clearly better than in HR-/HER2- or HR-/HER2+
tumors [32]. Regarding these results and our data presented
here, it is conceivable that patients with HR and HER2 co-
expressing breast carcinomas might constitute a group that
particularly benefits from neoadjuvant chemotherapy as dem-
onstrated by high pCR rates and favorable survival times. This
is in contrast to HR+/HER2- tumors that rarely respond but
nevertheless show favorable survival rates. The results accord-
ing to the response rate of HR-/HER2+ tumors are conflictive
as the studies cited above found high pCR rates in this sub-
group, in contrast to our results. Of note, neither in the Gepar-
duo cohort nor in the cohorts described above trastuzumab
had been included in the neoadjuvant therapy regime as this
was no standard at the time of study execution. As newer stud-
ies using trastuzumab in patients with HER2+ tumors have
shown almost doubled pCR rates, it will be compelling to elu-
cidate whether the predictive and prognostic effects
described above would be altered by the addition of anti-
HER2 agents.
Some interesting facts about the molecular interaction of hor-
mone receptors (particularly ER) and HER2 have been
reported to date: estrogen generally downregulates HER2
Figure 3
(A) Kaplan-Meier curve indicating disease-free survival times of patients in dependence of b east cancer subcl si icationa
in dependence of breast cancer subclassification. (b) Disease-free sur-
vival of patients who did not achieve a pCR in dependence of biology-
based tumor type. p: Cox regression.Page 8 of 11
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evant in HR/HER2 co-expressing carcinomas from hitherto
unknown reasons [16]. Moreover, ER can activate HER2 by
membrane non-genomic estrogen signaling, while HER2 acti-
vates ligand-independently ER by mitogen-activated protein
kinase (MAPK)-/protein kinase B (AKT)-mediated phosphor-
ylation [35]. These interactions have been supposed to be
underlying the relative resistance and worse prognosis of
breast cancers that co-express ER and HER2 and that have
been treated with tamoxifen [36]. However, the situation in
patients that are treated with primary chemotherapy is presum-
ably quite different and there are no functional data that explic-
itly refer to this group of tumors. In the adjuvant setting HER2+
tumors respond well to an anthracycline-based therapy [37]
and it is conceivable that this might be also the case in HR+/
HER2+ tumors in the neoadjuvant setting as reflected by high
pCR rates. For long-term prognosis the phenotype of HR pos-
itive tumors cells (higher differentiation, slower proliferation,
etc.) seems to be more relevant in receptor co-expressing
tumors and may even be amplified by HER2-mediated ER acti-
vation. Yet, the exact mechanisms remain to be elucidated in
future functional studies.
The other biology-based tumor type for which we found a par-
ticular behavior as to response and survival is the HR-/HER2-
(triple negative) subgroup. In line with previous reports in the
neoadjuvant and adjuvant setting [30-32,38-40], we observed
a relatively short survival time in spite of a high response rate.
Carey and Liedke explained this with the exceptionally poor
prognosis of patients with HR-/HER2- tumors not achieving a
pCR [31,32]. We also saw a higher rate of disease-relapses
in HR-/HER2- tumors without pCR than with pCR (42.1% vs.
20%). A predictive factor for neoadjuvant chemotherapy
response might thus also be a reliable prognostic factor in the
HR-/HER2- subtype. However, in our group highly proliferat-
ing tumors were more likely to respond, which may be
explained by the fact that actively dividing cells are the target
of cytotoxic drugs, but a high Ki67 labeling index was not
linked to a better prognosis. Independent of the biology-based
tumor type, Ki67 staining per se was an independent predic-
tive but no prognostic factor in the whole study group, indicat-
ing that as to long-term survival proliferation is not as relevant
as HR or HER2 expression. Yet, our findings support the con-
cept that HR-/HER2- carcinomas are a heterogeneous groups
of tumors which should be subdivided further [18,19]. The
expression of basal cytokeratins has been reported as one dis-
tinctive feature of the so-called basal-like carcinomas, a highly
aggressive breast cancer subtype according to the concept of
intrinsic breast cancer subtypes, which have been defined by
gene expression analysis [12]. In our whole study group CK5/
6 expression was a predictive factor, but within the HR-/
HER2- group the addition of CK5/6 expression did not add
predictive or prognostic information to the determination of
ER, PgR, and HER2, which however might have been a sam-
ple size problem. The problem with the poor-prognosis HR-/
HER2- tumors is that no specific targeted therapy exists to
date, in contrast to endocrine therapy in HR+ and trastuzumab
or lapatinib in HER2+ breast cancers. Our hypothesis of a
special predictive and prognostic role of COX-2 or YB-1-
expression (for both molecules targeted therapies are availa-
ble or are in development) [41,42] in HR-/HER2- carcinomas
could not be proven in our study.
Certain limitations of our study should be stated: Due to the
retrospective evaluation and the limited sample size it is prima-
rily a hypothesis-generating study, and results remain to be
investigated further in larger cohorts, preferentially in prospec-
tive trials [43]. However, the setting of a clinical trial ensures a
clearly described population, homogenous treatment as well
as well-documented and monitored data.
Conclusions
In summary, our results demonstrate that a breast cancer clas-
sification, simply based on the expression of the standard
markers ER, PgR, and HER2 bears independent predictive
and prognostic potential. Patients with HR-/HER2- tumors,
particularly those without achievement of a pCR, are in need
for further treatment options. Patients with HR-/HER+ tumors
had an unfavorable prognosis, but can now be treated with
anti-HER2 agents. In contrast, for HR+/HER2- carcinomas
pCR was not relevant for prognosis, as DFS was long in spite
of a low response rate. The HR+/HER2+ co-expressing carci-
nomas, so far insufficiently investigated, emerged as a group
of tumors with a good response rate to neoadjuvant anthracy-
cline/taxane chemotherapy and a favorable prognosis. This
interesting group of tumors should be further investigated in
prospective clinical trials and in functional studies.
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